Eric C. Jeschke
113 IP cases indexed. Covers patent matters.
Cases Presided Over
113 cases indexed | Page 3 of 4
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB held that Imperative Care proved all nine claims of Inari Medical’s 11,697,011 B2 hemostasis valve patent are unpatentable, finding the term “filament” must be flexible and that the prior art renders the claims obvious.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB decided to institute trial on all challenged claims of the '921 patent, despite preliminary evidence not supporting anticipation over Schaffer. The Board adopted a broad definition of 'filament' but ultimately found that the claim language required flexibility based on intrinsic and extrinsic teachings.
Eunsung Global Corp. v.HydraFacial LLC et al.
Eunsung Global Corp. and HydraFacial LLC settled their inter partes review disputes, leading the PTAB to terminate both IPRs before institution. The settlement agreement is treated as confidential business information.
Eunsung Global Corp. v.HydraFacial LLC et al.
Eunsung Global and HydraFacial settled their inter partes review disputes before the PTAB instituted a trial. The Board granted joint motions to terminate and to keep the settlement agreement confidential, ending the proceedings.
Imperative Care, Inc. v.Inari Medical, Inc.
The PTAB has instituted an inter partes review of Inari Medical’s 11,865,291 B2 hemostasis valve patent after finding Imperative Care’s petition shows a reasonable likelihood of success. All challenged claims (1‑8, 12‑19) are now subject to trial.
Imperative Care, Inc. v.Inari Medical, Inc.
The PTAB instituted an inter partes review of Inari Medical’s 11,697,012 B2 hemostasis valve patent after finding Imperative Care’s petition shows a reasonable likelihood of success on all nine challenged claims.
Imperative Care, Inc. v.Inari Medical, Inc.
The PTAB held that all nine claims of Inari Medical’s hemostasis‑valve patent are unpatentable. Petitioner Imperative Care proved anticipation and obviousness over Schaffer, Hartley, Eller and Garrison, with the Board emphasizing that the claimed filament must be flexible.
Imperative Care, Inc. v.Inari Medical, Inc.
The PTAB instituted an inter partes review of Inari Medical’s 11,844,921 B2 hemostasis valve patent after Imperative Care showed a reasonable likelihood of success. All challenged claims (1‑7, 9‑10, 15‑18, 20‑24) are now under review.
Imperative Care, Inc. v.Inari Medical, Inc.
The PTAB instituted an inter partes review of Inari Medical’s 11,697,011 B2 hemostasis valve patent after finding Imperative Care’s likelihood of success on at least one claim.
Imperative Care, Inc. v.Inari Medical, Inc.
The PTAB denied Imperative Care’s petition to institute an IPR against Inari Medical’s U.S. Patent 11,744,691, finding no reasonable likelihood of success. The Board concluded the cited prior art did not disclose the required negative‑pressure pump configuration.
Imperative Care, Inc. v.Inari Medical, Inc.
Imperative Care challenges Inari Medical's hemostasis valve patent (11554005) on obviousness grounds. The PTAB instituted the IPR, requiring further review of claims 1-15 based on prior art combinations.
Imperative Care, Inc. v.Inari Medical, Inc.
The PTAB denied the institution of an IPR challenge against Inari Medical's patent (11744691) covering emboli treatment systems. The Board found that the petitioner, Imperative Care, Inc., failed to demonstrate a reasonable likelihood of prevailing on its grounds of anticipation and obviousness.
Sinclair Pharma Limited et al. v.HydraFacial LLC
Sinclair Pharma Limited et al. successfully instituted IPR proceedings against HydraFacial LLC regarding skin treatment systems, finding a reasonable likelihood of obviousness over prior art references. The Board found that combining existing microdermabrasion and irrigation technologies renders the challenged claims unpatentable.
Globus Medical, Inc. v.Spinelogik, Inc.
Globus Medical successfully petitioned the PTAB to challenge Spinelogik's spinal fusion implant patents. The Board found a reasonable likelihood of unpatentability based on anticipation and obviousness over prior art references like Blain. This decision advances the dispute into active trial proceedings.
Kubota North America Corporation et al. v.Vermeer Manufacturing Company
Kubota North America Corporation successfully convinced the PTAB not to issue a discretionary denial of its IPR petition against Vermeer Manufacturing Company's patent. The Board found that Kubota demonstrated a reasonable likelihood of prevailing on at least one ground, allowing the case to proceed to full examination.
Kubota North America Corporation et al. v.Vermeer Manufacturing Company
Kubota North America Corporation successfully petitioned for institution in an IPR against Vermeer Manufacturing Company's '386 patent, asserting grounds of obviousness (103) and novelty (102). The Board found that the petitioner's arguments regarding prior art combinations were persuasive enough to overcome the Patent Owner's request for discretionary denial.
Dyson Technology Limited et al. v.Omachron Intellectual Property Inc. et al.
Dyson and Omachron settled their PTAB inter partes review disputes, leading to termination of four IPRs covering Dyson vacuum technology patents. The settlement agreement is treated as confidential business information.
Dyson Technology Limited et al. v.Omachron Intellectual Property Inc. et al.
Dyson successfully petitioned to institute IPR against Omachron Intellectual Property Inc.'s vacuum cleaner patent, asserting obviousness under 35 U.S.C. § 103. The Board found that Dyson adequately demonstrated a motivation to combine prior art references for several claimed features, leading to institution on 13 claims.
BabyBjorn AB et al. v.The Ergo Baby Carrier, Inc. et al.
The PTAB denied the institution of an IPR challenge against The Ergo Baby Carrier's patent on adjustable baby carriers. Petitioner failed to meet its burden of persuasion, specifically regarding the public accessibility of key prior art and demonstrating a reasonable likelihood of prevailing on the merits.
Eunsung Global Corp. v.HydraFacial LLC et al.
The PTAB denied institution for an IPR challenge regarding skin treatment systems due to substantial overlap with parallel ITC proceedings and advanced litigation. This decision emphasizes resource conservation when multiple venues address the same prior art.
Decent Espresso International Ltd. v.DUVALL ESPRESSO IP ENFORCEMENT, LLC
The PTAB denied Decent Espresso International Ltd.'s IPR challenge against DUVALL ESPRESSO IP ENFORCEMENT, LLC's infused beverage brewing assembly patent. The Board rejected the petitioner's claim construction of 'resulting solvent valve,' upholding the single-valve interpretation required by the patent owner.
Decent Espresso International Ltd. v.DUVALL ESPRESSO IP ENFORCEMENT, LLC
Decent Espresso International Ltd. failed its IPR challenge against Duvall Espresso's brewing system patent, as the Board found insufficient evidence that the prior art rendered the invention obvious. The institution decision denied the petition, maintaining the validity of the core claims related to infused beverage preparation.
STARA S.A.-INDÚSTRIA DE IMPLEMENTOS AGRÃCOLAS v.AGCO Corporation
The PTAB denied institution of the IPR, finding that the petitioner failed to demonstrate a reasonable likelihood of unpatentability for any challenged claim. The grounds relied on obviousness (103), utilizing combinations of prior art references including Hubalek and KR’062.
Klein Tools, Inc. v.Milwaukee Electric Tool Corporation et al.
The PTAB granted institution for a petition challenging 23 claims related to container assembly mechanisms, finding a reasonable likelihood of success on at least one ground. The Board found that the combination of multiple prior art references rendered the patent obvious, despite challenges from the Patent Owner regarding prior art consideration and lack of rationale.
Dyson Technology Limited et al. v.Omachron Intellectual Property Inc. et al.
Dyson and Omachron settled their IPR dispute over U.S. Patent 7,776,120, leading the PTAB to terminate the proceeding before any merits were decided.
Dyson Technology Limited et al. v.Omachron Intellectual Property Inc. et al.
Dyson and Omachron settled their inter partes review dispute over U.S. Patent 11,910,983 B2. The Board granted a joint motion to terminate the proceeding and treated the settlement agreement as confidential.
Imperative Care, Inc. v.Inari Medical, Inc.
The PTAB instituted an inter partes review of Inari Medical’s 11,554,005 B2 embolism‑treatment patent after finding Imperative Care likely to prevail on at least one claim, primarily on obviousness grounds involving hemostasis valve features.
Imperative Care, Inc. v.Inari Medical, Inc.
Imperative Care has successfully instituted an inter partes review of Inari Medical’s 11,697,011 hemostasis valve patent, asserting anticipation and obviousness over three prior‑art references. The Board found a reasonable likelihood of unpatentability on at least one claim and ordered the trial to proceed.
Imperative Care, Inc. v.Inari Medical, Inc.
Imperative Care challenges Inari Medical's hemostasis valve patents under grounds of anticipation and obviousness. The Board construed the key term 'filament' to require flexibility, which influenced its initial assessment of the claims. Institution was granted, setting the stage for a full trial on infringement and validity.
Imperative Care, Inc. v.Inari Medical, Inc.
The Board found that the claims were obvious over prior art references by combining known features to achieve a predictable result. Despite initial disputes over claim construction, the Petitioner failed to provide sufficient motivation for combining specific prior art elements.
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.